Role of Angio-Embolization for Renal Cell Carcinoma
Purpose of Review
To provide the technical aspects of, clinical indications for, status of the current literature on, and emerging concepts in trans-arterial embolization (TAE) for renal cell carcinoma.
TAE has been evaluated in several retrospective series as a neoadjuvant therapy prior to surgical resection of RCC to reduce tumor vascularity and minimize intra-operative blood loss. TAE has also been examined retrospectively as a neoadjuvant therapy prior to the percutaneous ablation of RCC to reduce blood loss and procedural complications. TAE can potentially palliate symptoms of RCC such as pain and hematuria. Trans-arterial chemoembolization and trans-arterial radioembolization are emerging concepts for RCC.
Although there have been no prospective, randomized trials demonstrating improved clinical or oncologic outcomes from TAE for patients with RCC, several retrospective studies have shown encouraging results.
KeywordsRenal cell carcinoma Embolization Ablation Nephrectomy Palliation
Compliance with Ethical Standards
Conflict of Interest
Andrew J. Gunn is a paid speaker for BTG.
Anand R. Patel declares no potential conflicts of interest.
Soroush Rais-Bahrami is a section editor for Current Urology Reports.
Human and Animal Rights
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.•• Talenfeld AD, Gennarelli RL, Elkin EB, Atoria CL, Durack JC, Huang WC, et al. Percutaneous ablation versus partial nephrectomy and radical nephrectomy for T1a renal cancer: a population-based analysis. Ann Intern Med. 2018; https://doi.org/10.7326/M17-0585. Large, population-based analysis of over 4300 patients over a 52-month period which demonstrates that percutaneous ablation has similar oncologic outcomes to radical nephrectomy in T1a disease with less detrimental effects on renal function and fewer procedure-related complications.
- 14.Gunn AJ, Mullenbach BJ, Poundstone MM, Gordetsky JB, Underwood ES, Rais-Bahrami S. Trans-arterial embolization of renal cell carcinoma prior to percutaneous ablation: technical aspects, institutional experience, and brief review of the literature. Curr Urol. 2018; In pressGoogle Scholar
- 15.Yamakado K, Nakatsuka A, Kobayashi S, Akeboshi M, Takaki H, Kariya Z, et al. Radiofrequency ablation combined with renal arterial embolization for the treatment of unresectable renal cell carcinoma larger than 3.5 cm: initial experience. Cardiovasc Intervent Radiol. 2006;29(3):389–94.CrossRefPubMedGoogle Scholar
- 18.• Arima K, Yamakado K, Kinbara H, Nakatsuka A, Takeda K, Sugimura Y. Percutaneous radiofrequency ablation with transarterial embolization is useful for treatment of stage 1 renal cell carcinoma with surgical risk: results at 2-year mean follow up. Int J Urol. 2007;14(7):585–90. Largest retrospective series analyzing the utility of trans-arterial embolization prior to percutaneous ablation in RCC showing technical feasibility and no hemorrhagic complications. CrossRefPubMedGoogle Scholar
- 28.• Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol. 2000;23(1):6–12. Retrospective analysis of pre-surgical trans-arterial embolization of RCC with a comparison to a control group matched for several clinical factors demonstrated a 5- and 10-year survival benefit for embolization. CrossRefPubMedGoogle Scholar
- 29.• May M, Brookman-Amissah S, Pflanz S, Roigas J, Hoschke B, Kendel F. Pre-operative renal arterial embolization does not provide survival benefit in patient with radical nephrectomy for renal cell carcinoma. Br J Radiol. 2009;82(981):724–31. Retrospective analysis of pre-surgical embolization of RCC in 227 patients failed to show any clinical benefits to the additional procedure. CrossRefPubMedGoogle Scholar
- 31.Schmit CH, Callstrom MR, Boorjian SA, Johnson MP, Atwell TD, Kurup AN, et al. A comparison of bleeding complications in patients undergoing percutaneous renal cryoablation using cryoprobes with and without heat-based track ablation. J Vasc Interv Radiol. 2018;29(6):874–9.CrossRefPubMedGoogle Scholar
- 33.•• Miller JM, Julien P, Wachsman A, Van Allan RJ, Friedman ML. The role of embolization in reducing complications of cryoablation in renal cell carcinoma. Clin Radiol. 2014;69(10):1045–9. Small retrospective analysis that showed a reduced rate of complications for percutaneous cryoablation in RCC if the tumor was embolized prior to the procedure. CrossRefPubMedGoogle Scholar
- 34.•• Gunn AJ, Mullenbach BJ, Poundstone MM, Klimkowski S, Gordetsky JB, Underwood ES, et al. Trans-arterial embolization of renal cell carcinoma as an adjunctive therapy prior to cryoablation: a propensity score matching analysis. Diagn Interv Radiol 2018. In press. Retrospective propensity score matching analysis that failed to demonstrate an objective benefit to trans-arterial embolization prior to percutaneous cryoablation in RCC. Google Scholar
- 36.• Serafin Z, Karolkiewicz M, Strzesniewski P, Lasek W, Bryczkowski M, Wolski Z. Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: safety and symptom control. Med Sci Monit. 2007;13(Suppl 1):98–104. Largest retrospective series assessing the utility of trans-arterial embolization as a palliative approach in RCC showed improvements in both pain and hematuria. PubMedGoogle Scholar
- 39.• Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. BJU Int. 2001;87(4):312–5. Retrospective study comparing the outcomes of trans-arterial therapy to best supportive care in patients with inoperable RCC showed good symptom control in the therapy group with a prolonged survival. CrossRefPubMedGoogle Scholar
- 40.•• Karalli A, Ghaffarpour R, Axelsson R, Lundell L, Bozoki B, Brismar T, et al. Transarterial chemoembolization of renal cell carcinoma: a prospective controlled trial. J Vasc Interv Radiol. 2017;28(12):1664–72. Small, randomized, controlled study comparing trans-arterial embolization to trans-arterial chemoembolization prior to surgery in RCC. RCCs treated with chemoembolization showed more necrosis on post-procedural imaging than those treated with trans-arterial embolization. CrossRefPubMedGoogle Scholar
- 41.•• Clark W, Aslan P, Patel M, Vass J, Cade D, de Silva S, et al. The RESIRT study: feasibility and dosimetry considerations of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres in patients with primary renal cell carcinoma (RCC). J Vasc Interv Radiol. 2017;28(2 Suppl):S164. Phase I clinical study demonstrating the safety of radioembolization in patients with RCC. CrossRefGoogle Scholar